In spite of an estimated 500,000 new annual cases of children with tuberculosis (TB), there are no appropriate medicines for them, UNITAID and the TB Alliance warn. TB, one of the worlds most neglected diseases with almost no new treatments developed in the past 50 years, is one of the top ten causes of childhood death. TB mostly affects the worlds poorest; among those, the most vulnerable are children.
With no alternatives available, treatment providers for children are forced to adapt medicines for adults as best they can, such as by cutting pills. This leads to improper treatment, treatment failure, spread of this highly-contagious disease, and conditions ripe for the development of drug-resistant strains of the bacteria which causes the disease.
In response to this need, UNITAID is funding a TB Alliance project to develop a correctly-dosed child-friendly first-line TB treatment which is expected to be available within three years. This work will also help speed the development of other regimens for children that are now in the pipeline.
Despite the worlds capabilities to address this disease, paediatric tuberculosis has been ignored for far too long, resulting in a complete lack of appropriate medicines, says Denis Broun, executive director of UNITAID. This project is designed to spur innovation so that the right kinds of treatments are available as quickly as possible and at affordable prices. We now need other global players to also step up, especially for identifying those children affected.
The extent of the childhood TB pandemic is not fully understood. Most experts believe that TB in children goes largely undiagnosed and that the true scope of the problem is far higher than the estimates today.
Developing treatments for children with TB is an urgent humanitarian imperative, says Mel Spigelman, MD, president and CEO of TB Alliance. An appropriate formulation for the decades-old drugs is not even available. We need to immediately rectify the situation for the present drugs, and also ensure that the improved treatments in the pipeline will be developed for children soon after they are approved for adults.
In 2010, the World Health Organization released new guidelines for paediatric medications. However, to date, no quality-assured products have been produced to these specifications.
World TB Day, March 24, commemorates the day in 1882 that Robert Koch discovered the tubercle bacillus, the bacteria responsible for tuberculosis. Since that discovery, progress against the disease has surged and ebbed. Now with outbreaks of more deadly forms of TB, documented around the world, its time to help protect children from this disease.
Source:Â UNITAID and Global Alliance for TB Drug Development
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.